Clinicopathological analysis showed that high ADORA2B expression has significantly reverse correlation with four important clinical parameters, ER positivity (P < 0.01), PgR positivity (P = 0.027), EGFR positivity (P < 0.01) and tumor size (P = 0.037), but not HER-2 positivity (P = 0.77) (Table 1). Here, ADORA2B is linked to neoplasm.